Omnicare — Q1 2013 Earnings Presentation
17 slides from Omnicare's earnings presentation, Apr 24, 2013
Slide 1: Omnicare
Omnicare
Slide 2: Forward-Looking Statements
Forward-Looking Statements Certain of mace lovey it i the following re fe ‘d-lookir i i vate ities Litigation Reform Act of 1995. These forward-| Hooking statements include, but are not tte to, all statements ir ue intent, belief or Current regarding Such and involve k and orleaan risks, uncertainti
Slide 3: Table of Contents
Table of Contents Rirst-Quarter 2013: HIQhliGht vcs cscessssascececeness a ues ususarsaveverers cnssersexensatereee 4 _ Operating Metrics — Script Data | Operating Metrics — Long-Term Care Bed Data... Gross Profit & Adjusted Operating Income Adjusted Net Income & Cash EPS....... Adjusted Operating I
Slide 4: First-Quarter 2013 Highlights
First-Quarter 2013 Highlights Gross profit of $370.8M; gross margin expanded 121 bps to 24.32%; _ + Adjusted cash earnings per diluted share) of $0.90; 11.1% higher than ' 1Q12 of $0.81 Cash flows from operations of $108.9M; 8.5% year-over-year increase SG&A expenses declined 5.7% sequentially to $2
Slide 5: Operating Metrics - Script Data
Operating Metrics _ Script Data Increase / Increase / (In thousands, except %s) 1Q2013 4Q2012 (Decrease) _1Q 2012 ‘Decrease Long-Term Care Group Scripts: Generic scripts eileen 20,809 21,109 (1.4%) 20,361 2.2% Branded scripts dispens 4,322 4,049 6.7% 5,083 (15.0%) Over-the-counter scripts ispaneed 3
Slide 6: Operating Metrics - Long-Term Care Bed Data
Operating Metrics Long-Term Care Bed Data Sequential Prior Year Increase / Increase / (in thousands) 1Q2013 4Q2012 (Decrease) 12012 (Decrease) Beds served: Beginning of period - LTC Beds 970 980 (10) 1,010 (40) Net change in beds served 4 10) 9 (24) 23 End of period - LTC Beds 969 970 (1) 986 (17) P
Slide 7: Gross Profit & Adjusted Operating Income
Gross Profit & Adjusted Operating Income )2) Prior Year Increase / Increase / In millions, except per share data and %s 1Q2013 _4Q2012 (Decrease) _1@2012 (Decrease! t sales $ 1,525.0 $ 1,529.9 (0.3%) $ 1,593.1 (4.3%) Cost of sales 1154.2 1,153.3 0.1% 1,225.0 (5.8%) Gross profit $ 3708 $ 3767 (1.6%)
Slide 8: Adjusted Net Income & Cash-based EPS
1 B Adjusted Net Income & Cash-based EPS) Sequential Prior Year Increase / Increase / ia ee era pale state data and %s 12013 _4Q2012_ (Decrease) _1@2012 (Decrease) operatin $ 144.8 ~$ 135.7 67% $§ 143.6 0.8% achat interest expense: net of investment income (23.4) (23.7) (1.3%) (24.5) (4.5%) Adjusted
Slide 9: Adjusted Operating Income by Segment
Adjusted Operating Income by Segment (1) Sequet Prior Year se | 1Q 2013 4Q 2012 icecieess) 1Q 2012 qOecrsass) In millions, except %s Long-Term Care Group Net sales $ 1,155.1 $ 1,183.6 (2%) $ tees Cry 15: 155.0 Adjusted operating income” 5. fo Rate 13.42% 13.10% 32 bps i So 152 es In whole numbers Pe
Slide 10: Cash Flows
Cash Flows “) in haere except %s nat to reconcile net income to net cash flows from operating activities De rection expense Amortization ex, ities, net of effects from acquisition and divestiture of businesses Net cash flows from operating activities Capital expenditures Dividends paid Free cash flo
Slide 11: Cash Deployment
i " Cash Deployment Sequential Increase / 1Q 2013 4Q2012 (Decrease) 1Q 2012 In millions, except %s Net cash flows from operating activities (reported) ~$ 108.9 Capital expenditures 23.41 Acquisitions - Net debt and long term borrowings repayment “) 7.0 Capital returned: Dividends paid $ 145 Share re
Slide 12: Full-Year 2013 Guidance
Full-Year 2013 Guidance Pe Previous Guidance “) | Current Guidance @ » Revenue $6.1B to $6.2B $6.1B to $6.2B + Adjusted cash earnings per diluted ae $3.47 to $3.57 $3.47 to $3.57 * Cash flow from operations $450M to $500M $450M to $500M 4, Guidance provided on February 19,2018 2 Guitare proved on Ap
Slide 13: Appendix
RNY ly, “yg; Omnicare Appendix
Slide 14: Capital Structure
Capital Structure Major Debt Maturity Schedule) (in $ millions) $1,500 | was of 9/30/10 WAs of 3/31/13 $0 2010 2015 2020 2025 2030 2035 2040
Slide 15: Working Capital Management
Working Capital Management Five Quarter Trend() 65 208 298 20, 273 — 2 263 20 55 10 50 49.6 ° 45 1012 2012 3012 412 1013 1. _DOH= Ending Inventory (Quarry Cost of Sales /Daysin Quart) DSO = Ending Account Receivable (Quarterly Sles/Daysin Quai)
Slide 16: Selected Branded Drug Patent Expirations
1Q 2013 2Q-4Q 2013 Lamictal XR Aciphex Luvox CR Aricept 23 Maxalt/Maxalt MLT Asacol ‘Mucinex (evauren) Atacand IR Suboxone Cymbalta Fosrenol Lidoderm Lunesta Niaspan Prandin Prevacid Soltab “e!2em) Rilutek Temodar Xeloda ib 2 Drugsatready launched shown in ray and tals FY 2014 Actonel Avelox Celebre
Slide 17: Omnicare
Omnicare